The Standard of Care: Managing Your PV Over Time

The primary goals of treating Polycythemia Vera (PV) are to prevent blood clots and to manage symptoms that interfere with your daily life ^[1][2]. Because PV is a chronic condition, your treatment plan will be a marathon, not a sprint, and may evolve over many years.

The Gold Standard: The 45% Rule

Regardless of which medications you take, the single most important goal is to keep your hematocrit (HCT) below 45% ^[3][2].

This target is based on a major clinical study (the CYTO-PV trial) which proved that patients who kept their HCT below 45% had a four-fold lower risk of dying from cardiovascular issues or suffering a major blood clot compared to those who allowed their HCT to rise even slightly higher (45–50%) ^[3].

Foundation Treatments for Everyone

Almost every patient with PV, regardless of their risk level, will use these two foundational treatments ^[4][5]:

1. Phlebotomy

This is the physical removal of a unit of blood (similar to a blood donation). It is the fastest way to lower your hematocrit and “thin” your blood ^[6][2].

Warning: Phlebotomy works by intentionally making your body iron-deficient to slow down red blood cell production ^[5]. Never take over-the-counter iron supplements without asking your MPN specialist. Taking iron can dangerously fuel the disease and spike your hematocrit, completely undoing the benefits of phlebotomy. You may experience symptoms of iron deficiency, such as craving ice (pica) or restless legs. Report these to your doctor rather than self-treating.

2. Low-Dose Aspirin

This typically involves taking an 81mg aspirin daily to keep your platelets from sticking together, further reducing the risk of clots in your arteries and veins ^[7][1].

Warning: While blood clots are the primary risk, some patients with extremely high platelets (over 1 million) may have an increased risk of bleeding (a condition called acquired von Willebrand syndrome). Your doctor may pause your aspirin in this case. Additionally, avoid taking other NSAID pain relievers (like ibuprofen or naproxen) regularly alongside your aspirin without consulting your doctor, as this increases the risk of bleeding ^[7].

Choosing Your Path: Low Risk vs. High Risk

Doctors use a simple “decision tree” to determine if you need additional medication (cytoreductive therapy) to lower your blood counts ^[4][8].

Note: The treatment landscape is constantly evolving. Some MPN specialists now consider starting disease-modifying medications (like Ropeginterferon) earlier, even for “Low Risk” patients, rather than waiting for them to progress to high risk ^[9].

Common Medications (Cytoreductive Therapy)

If you require medication to control your PV, your doctor will likely discuss these three options:

1. Hydroxyurea (HU)

Historically the first-line choice for high-risk PV ^[4].

• How it works: It is an oral capsule that slows down the production of all blood cells in the bone marrow ^[10].
• Safety Caveats: Patients on Hydroxyurea have an increased risk of non-melanoma skin cancers. Regular skin checks by a dermatologist and strict sun protection are essential ^[11]. Additionally, it can cause leg ulcers or mouth sores, and is generally not recommended for patients who are pregnant or planning to have children ^[12].

2. Ropeginterferon alfa-2b (Besremi)

A newer, long-acting injection (usually given every two weeks) ^[9].

• How it works: It uses your body’s immune system to control the overactive bone marrow ^[13].
• Benefits: Unlike other drugs, interferons can sometimes lead to a “molecular remission,” meaning they actually reduce the amount of the JAK2 mutation in your blood ^[9][14].
• Safety Caveats: Interferons can sometimes cause mood changes, depression, or flu-like symptoms ^[9].

3. Ruxolitinib (Jakafi)

Typically used as a “second-line” treatment for patients who do not respond well to Hydroxyurea ^[15][16].

• How it works: It is a JAK inhibitor that specifically targets the overactive signaling pathway caused by the JAK2 mutation ^[17].
• Benefits: It is exceptionally good at shrinking an enlarged spleen and reducing “constitutional” symptoms like severe itching and night sweats ^[15][18].
• Safety Caveats: Ruxolitinib carries a risk of non-melanoma skin cancer and shingles. Your doctor may recommend a shingles vaccine before you begin treatment ^[15].

When is it time to switch?

If you are on Hydroxyurea but still require frequent phlebotomies to stay under 45%, or if your symptoms (like itching or fatigue) are getting worse, you may be resistant to that treatment ^[19][20]. If the medicine causes painful side effects like skin ulcers, you are considered intolerant ^[11]. In either case, current guidelines recommend switching to a different therapy like Ruxolitinib or Interferon ^[15][17].